Comparative Pharmacology
Head-to-head clinical analysis: MAXZIDE 25 versus ORETICYL 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXZIDE 25 versus ORETICYL 25.
MAXZIDE-25 vs ORETICYL 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Maxzide-25 is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, and triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the collecting duct by blocking epithelial sodium channels.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive NaCl cotransporter, increasing excretion of sodium, chloride, and water. Deserpidine depletes catecholamines from peripheral sympathetic nerve endings by binding to the vesicular monoamine transporter, reducing vascular resistance and heart rate.
1 tablet (triamterene 37.5 mg/hydrochlorothiazide 25 mg) orally once daily.
Hydrochlorothiazide 25 mg orally once daily; may increase to 50 mg daily if needed.
None Documented
None Documented
Triamterene: 2-4 hours (terminal half-life due to active metabolite hydroxylated triamterene, clinical effect persists 12-16 hours). Hydrochlorothiazide: 5.6-14.8 hours (mean 8.5 hours).
2.5 hours; in renal impairment may extend to 8–15 hours.
Renal: triamterene 80-85% (as metabolites, 5-10% unchanged), hydrochlorothiazide ≥95% unchanged via tubular secretion; biliary/fecal: minimal (<5% each).
Primarily renal (95% unchanged); minimal biliary (<5%).
Category C
Category C
Diuretic Combination
Diuretic Combination